有胰腺炎病史的个体接受 GLP-1 受体激动剂治疗后发生急性胰腺炎的发生率。
The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis.
机构信息
Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA.
Carolina Health Specialist, Myrtle Beach, SC, USA.
出版信息
Diabetes Res Clin Pract. 2024 Sep;215:111806. doi: 10.1016/j.diabres.2024.111806. Epub 2024 Aug 5.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been reported to increase the risk of acute pancreatitis (AP). This real-world study did not observe a higher frequency of AP with GLP-1RA exposure in adults with T2D and a prior history of AP regardless of etiology.
摘要
胰高血糖素样肽-1 受体激动剂（GLP-1RA）已被报道会增加急性胰腺炎（AP）的风险。这项真实世界研究未观察到 2 型糖尿病（T2D）合并 AP 既往史的成人在使用 GLP-1RA 后出现 AP 频率更高的情况，无论病因如何。
Zotero 插件